Research
Hormonal
Bariatric surgery (specifically gastric bypass) leads to elevated levels of GLP-1 and PYY, which are linked to enhanced delivery of nutrients to the distal intestine and underlie beneficial outcomes on weight loss and glycemia.
Bariatric surgery works partly by changing how your gut senses food, leading to higher levels of satiety hormones like GLP-1 and PYY, which help with weight loss and blood sugar control.
GoodSupportsHIGH confidence
It is believed that the markedly elevated levels of GLP1 and PYY following gastric bypass surgery are linked to enhanced delivery of nutrients to the distal intestine and underlie many of the beneficial outcomes on weight loss and glycemia (1).
Why this rating
Cited as a well-established phenomenon with multiple references.
Source
Gut chemosensing mechanisms
Arianna Psichas et al. · Journal of Clinical Investigation · 2015
DOI 10.1172/jci76309
narrative_reviewCited 237×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Ingestion of carbohydrates, proteins, and lipids stimulates enteroendocrine cells (EECs) to secrete gut hormones (GLP-1, GIP, CCK, PYY) via specific nutrient-sensing receptors and transporters, which modulates glucose homeostasis, appetite, and gastrointestinal motility.Good
- SGLT1-mediated glucose uptake is the primary mechanism for early glucose-stimulated GLP-1 and GIP secretion, whereas metabolism-dependent pathways play a lesser role in peak early secretion.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →